BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
34.25
+0.88 (2.64%)
At close: May 30, 2025, 4:00 PM
33.54
-0.71 (-2.07%)
After-hours: May 30, 2025, 7:27 PM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for BridgeBio Pharma stock ranges from a low of $45 to a high of $95. The average analyst price target of $57.09 forecasts a 66.69% increase in the stock price over the next year.
Price Target: $57.09 (+66.69%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 30, 2025.
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $52 → $55 | Buy | Maintains | $52 → $55 | +60.58% | Apr 30, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $46 → $63 | Buy | Maintains | $46 → $63 | +83.94% | Apr 30, 2025 |
| UBS | UBS | Strong Buy Maintains $65 → $72 | Strong Buy | Maintains | $65 → $72 | +110.22% | Apr 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $53 | Strong Buy | Maintains | $49 → $53 | +54.74% | Apr 15, 2025 |
| Redburn Atlantic | Redburn Atlantic | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +45.99% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
419.62M
from 221.90M
Increased by 89.10%
Revenue Next Year
659.11M
from 419.62M
Increased by 57.07%
EPS This Year
-3.23
from -2.88
EPS Next Year
-2.05
from -3.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 644.4M | 948.9M | 1.8B | ||
| Avg | 419.6M | 659.1M | 1.2B | ||
| Low | 212.7M | 328.3M | 569.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 190.4% | 126.1% | 167.5% | ||
| Avg | 89.1% | 57.1% | 88.0% | ||
| Low | -4.2% | -21.8% | -13.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.53 | -1.28 | 1.85 | ||
| Avg | -3.23 | -2.05 | 0.04 | ||
| Low | -3.85 | -3.25 | -1.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.